About EB

For many families, EB wound care is associated with constant effort and uncertain progress^1-3

Healing can be slow and inconsistent
Frequent dressing changes can add to the burden
Families continue to look for options that give them more control

With some therapies, several wounds may be left behind, highlighting the need for comprehensive wound care

Therapies limited by wound type, location, EB subtype, or even treatment volume force difficult choices and compromise comprehensive healing

EB patients and caregivers need wound care options that put control back in their hands—ones that allow⁴:

Early initiation at the first sign of new wounds
At-home use without additional clinic visits
Coverage across all wounds, not just selected areas
Easy integration into daily bandage routines

Discover how FILSUVEZ fits into a comprehensive wound care plan

About FILSUVEZ

Important Safety Information & Indication

Important Safety Information

Warnings & Precautions

Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

Important Safety Information & Indication

Important Safety Information

Warnings & Precautions

Adverse Reactions

The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).

Patient Counseling Information

Please refer to Prescribing Information for administration instructions.

To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information.

Indication

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.

References:

1. Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614-627.

2. Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78. doi:10.1038/s41572-020-0210-0

3. Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1. doi:10.1186/s13023-019-1279-y

4. FILSUVEZ (birch triterpenes) topical gel [prescribing information]. Chiesi USA; 2024.

PP-RA-01343 V1.0

The challenges of dystrophic and junctional epidermolysis bullosa wound management

Important Safety Information & Indication

Important Safety Information

Indication

Important Safety Information & Indication

Important Safety Information

Indication